Skip to main content
Top
Gepubliceerd in: Netherlands Heart Journal 2/2013

01-02-2013 | Special Article

Renal denervation: a new treatment option in resistant arterial hypertension

Auteurs: W. L. Verloop, M. Voskuil, P. A. Doevendans

Gepubliceerd in: Netherlands Heart Journal | Uitgave 2/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Hypertension is one of the most prevalent cardiovascular risk factors. Despite this high prevalence and a broad availability of effective pharmaceutical agents, a significant proportion of patients do not reach treatment goals. Partly this can be explained by secondary causes of hypertension or non-compliance of patients. Nevertheless, a subgroup of patients can be diagnosed with ‘resistant hypertension’. Activation of the sympathetic nervous system is known to be an important factor in the development and progression of systemic hypertension. In this context, a percutaneous, catheter–based approach has been developed using radiofrequency energy to disrupt renal sympathetic nerves. The first studies have shown this technique to be safe, illustrated by a lack of vascular or renal injury. More importantly, catheter-based renal nerve ablation resulted in a significant reduction in blood pressure on top of traditional medical therapy. Additional to the encouraging effects shown on hypertension, a positive influence of this intervention in other conditions, characterised by sympathetic overactivation, may be expected. Though this technique seems promising, further studies are needed to address long-term safety and efficacy of renal denervation in hypertension and other disease states.
Literatuur
1.
go back to reference Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.PubMed Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.PubMed
2.
go back to reference Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303:2043–50.PubMedCrossRef Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303:2043–50.PubMedCrossRef
3.
go back to reference Pereira M, Lunet N, Azevedo A, et al. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009;27:963–75.PubMedCrossRef Pereira M, Lunet N, Azevedo A, et al. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009;27:963–75.PubMedCrossRef
4.
go back to reference Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.PubMedCrossRef Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.PubMedCrossRef
5.
go back to reference Doumas M, Papademetriou V, Douma S, et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens. 2010;2011:318549.PubMed Doumas M, Papademetriou V, Douma S, et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens. 2010;2011:318549.PubMed
6.
go back to reference Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195–201.PubMedCrossRef Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195–201.PubMedCrossRef
7.
go back to reference Anderson EA, Sinkey CA, Lawton WJ, et al. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension. 1989;14:177–83.PubMedCrossRef Anderson EA, Sinkey CA, Lawton WJ, et al. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension. 1989;14:177–83.PubMedCrossRef
8.
go back to reference Siddiqi L, Joles JA, Grassi G, et al. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens. 2009;27:1341–9.PubMedCrossRef Siddiqi L, Joles JA, Grassi G, et al. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens. 2009;27:1341–9.PubMedCrossRef
9.
go back to reference Barajas L, Liu L, Powers K. Anatomy of the renal innervation: intrarenal aspects and ganglia of origin. Can J Physiol Pharmacol. 1992;70:735–49.PubMedCrossRef Barajas L, Liu L, Powers K. Anatomy of the renal innervation: intrarenal aspects and ganglia of origin. Can J Physiol Pharmacol. 1992;70:735–49.PubMedCrossRef
10.
go back to reference DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003;41(3 Pt 2):621–4.PubMedCrossRef DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003;41(3 Pt 2):621–4.PubMedCrossRef
11.
go back to reference DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75–197.PubMed DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75–197.PubMed
12.
go back to reference Kopp U, Aurell M, Sjolander M, et al. The role of prostaglandins in the alpha- and beta-adrenoceptor mediated renin release response to graded renal nerve stimulation. Pflugers Arch. 1981;391:1–8.PubMedCrossRef Kopp U, Aurell M, Sjolander M, et al. The role of prostaglandins in the alpha- and beta-adrenoceptor mediated renin release response to graded renal nerve stimulation. Pflugers Arch. 1981;391:1–8.PubMedCrossRef
13.
go back to reference Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659–82.PubMed Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659–82.PubMed
14.
go back to reference Atherton DS, Deep NL, Mendelsohn FO. Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study. Clin Anat. 2012;25:628–33.PubMedCrossRef Atherton DS, Deep NL, Mendelsohn FO. Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study. Clin Anat. 2012;25:628–33.PubMedCrossRef
16.
go back to reference Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152:1501–4.PubMedCrossRef Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152:1501–4.PubMedCrossRef
17.
go back to reference Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1(6757):403–8.PubMedCrossRef Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1(6757):403–8.PubMedCrossRef
18.
go back to reference Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.PubMedCrossRef Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.PubMedCrossRef
19.
go back to reference Voskuil M, Verloop WL, Blankestijn PJ, et al. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J. 2011;19:319–23.PubMedCrossRef Voskuil M, Verloop WL, Blankestijn PJ, et al. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J. 2011;19:319–23.PubMedCrossRef
20.
go back to reference Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9.PubMedCrossRef Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9.PubMedCrossRef
21.
go back to reference Symplicity HTN-1 investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7. Symplicity HTN-1 investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.
22.
go back to reference Sobotka P. Symplicity HTN-1: long term follow-up of catheter-based renal sympathetic denervation for resistant hypertension confirms durable blood pressure reduction. 61st An-nual Scientific Session & Expo 2012. Chicago: Oral presentation at ACC; 2012. Sobotka P. Symplicity HTN-1: long term follow-up of catheter-based renal sympathetic denervation for resistant hypertension confirms durable blood pressure reduction. 61st An-nual Scientific Session & Expo 2012. Chicago: Oral presentation at ACC; 2012.
23.
go back to reference Egan BM. Renal sympathetic denervation: a novel intervention for resistant hypertension, insulin resistance, and sleep apnea. Hypertension. 2011;58:542–3.PubMedCrossRef Egan BM. Renal sympathetic denervation: a novel intervention for resistant hypertension, insulin resistance, and sleep apnea. Hypertension. 2011;58:542–3.PubMedCrossRef
24.
go back to reference Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–6.PubMedCrossRef Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–6.PubMedCrossRef
25.
go back to reference Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901–9.PubMedCrossRef Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901–9.PubMedCrossRef
26.
go back to reference Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29:991–6.PubMedCrossRef Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29:991–6.PubMedCrossRef
27.
go back to reference Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559–65.PubMedCrossRef Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559–65.PubMedCrossRef
28.
go back to reference Tsioufis C, Dimitriadis K, Tsiachris D, et al. Catheter-based renal sympathetic denervation for the treatment of resistant hypertension: first experience in Greece with significant ambulatory blood pressure reduction. Hellenic J Cardiol. 2012;53:237–41.PubMed Tsioufis C, Dimitriadis K, Tsiachris D, et al. Catheter-based renal sympathetic denervation for the treatment of resistant hypertension: first experience in Greece with significant ambulatory blood pressure reduction. Hellenic J Cardiol. 2012;53:237–41.PubMed
29.
go back to reference Ahmed H, Neuzil P, Skoda J, et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv. 2012;5:758–65.PubMedCrossRef Ahmed H, Neuzil P, Skoda J, et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv. 2012;5:758–65.PubMedCrossRef
30.
go back to reference Gaspar Hernandez J, Eid-Lidt G, Payro Ramirez G, et al. Renal sympathetic denervation (RSD): a new, non-pharmacologic therapeutic strategy for treatment-resistant hypertension (TRH). Report of the first procedure in Mexico. Gac Med Mex. 2012;148:125–9.PubMed Gaspar Hernandez J, Eid-Lidt G, Payro Ramirez G, et al. Renal sympathetic denervation (RSD): a new, non-pharmacologic therapeutic strategy for treatment-resistant hypertension (TRH). Report of the first procedure in Mexico. Gac Med Mex. 2012;148:125–9.PubMed
31.
go back to reference Ong PJ, Foo D, Ho HH. Successful treatment of resistant hypertension with percutaneous renal denervation therapy. Heart. 2012;98(23):1754–5. Ong PJ, Foo D, Ho HH. Successful treatment of resistant hypertension with percutaneous renal denervation therapy. Heart. 2012;98(23):1754–5.
32.
go back to reference Simonetti G, Spinelli A, Gandini R, et al. Endovascular radiofrequency renal denervation in treating refractory arterial hypertension: a preliminary experience. Radiol Med. 2012;117:426–44.PubMedCrossRef Simonetti G, Spinelli A, Gandini R, et al. Endovascular radiofrequency renal denervation in treating refractory arterial hypertension: a preliminary experience. Radiol Med. 2012;117:426–44.PubMedCrossRef
33.
go back to reference Prochnau D, Figulla HR, Surber R. Efficacy of renal denervation with a standard EP catheter in the 24-h ambulatory blood pressure monitoring-long-term follow-up. Int J Cardiol. 2012;157:447–8.PubMedCrossRef Prochnau D, Figulla HR, Surber R. Efficacy of renal denervation with a standard EP catheter in the 24-h ambulatory blood pressure monitoring-long-term follow-up. Int J Cardiol. 2012;157:447–8.PubMedCrossRef
34.
go back to reference Worthley S. Safety and efficacy of a novel quadrapolar renal denervation catheter in patients with resistant hypertension: a first-in-man multicentre study. Paris: Oral presentation at EuroPCR; 2012. Worthley S. Safety and efficacy of a novel quadrapolar renal denervation catheter in patients with resistant hypertension: a first-in-man multicentre study. Paris: Oral presentation at EuroPCR; 2012.
35.
go back to reference Margolis JR, Percutaneous RF. balloon-mediated renal denervation in under a minute: The V2 System by Vessix. Frankfurt: Oral presentation at TrenD; 2012. Margolis JR, Percutaneous RF. balloon-mediated renal denervation in under a minute: The V2 System by Vessix. Frankfurt: Oral presentation at TrenD; 2012.
36.
go back to reference Mabin TA. REDUCE First-In-Man clinical study. Frankfurt: Oral presentation at TrenD; 2012. Mabin TA. REDUCE First-In-Man clinical study. Frankfurt: Oral presentation at TrenD; 2012.
Metagegevens
Titel
Renal denervation: a new treatment option in resistant arterial hypertension
Auteurs
W. L. Verloop
M. Voskuil
P. A. Doevendans
Publicatiedatum
01-02-2013
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 2/2013
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-012-0357-8

Andere artikelen Uitgave 2/2013

Netherlands Heart Journal 2/2013 Naar de uitgave